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Metabolic alterations such as insulin resistance are thought
to underlie the endothelial dysfunction and low grade inflam-
mation found in morbid obesity. Twenty-six morbidly obese
patients, aged 39.0  10.0 (mean  SD), were evaluated before
and 4.2  0.8 months after bariatric surgery. A marked incre-
ment in the insulin sensitivity index (SI) and the endothelium-
dependent vasodilatory response in a dorsal hand vein was
observed after weight loss following bariatric surgery. Circu-
lating levels of E-selectin, P-selectin, plasminogen activator
inhibitor-1, and von Willebrand factor, which were higher
than those in the control group, decreased significantly after
surgery. Plasma vascular cell adhesion molecule-1, angioten-
sin-converting enzyme, intercellular adhesion molecule-1,
thrombomodulin, and plasma and intraplatelet cGMP levels
did not change after weight loss. All inflammatory markers
were higher in morbidly obese patients. After surgery, C-
reactive protein and sialic acid diminished, whereas circu-
lating levels of IL-6, TNF-, and its soluble receptors did not.
Positive correlations were found between changes in adipos-
ity and SI and changes in C-reactive protein and between
changes in sialic acid and changes in endothelial function. In
conclusion, a marked improvement in SI, endothelial func-
tion, and low grade inflammation was observed in the weight-
losing, morbidly obese patients after bariatric surgery. SI and
adiposity appear to play roles in obesity-related, low grade
inflammation that contribute to the endothelial dysfunction
observed in morbid obesity. (J Clin Endocrinol Metab 90:
316–322, 2005)
THE MASSIVE ACCUMULATION of body fat observedin morbid obesity has been associated with hyperin-
sulinemia and insulin resistance (IR), which appear to be the
cornerstone of the obesity-related metabolic syndrome (1).
Obesity and IR are associated with higher levels of circulat-
ing endothelial dysfunction biomarkers such as soluble in-
tercellular adhesion molecule-1 (ICAM-1), soluble E-selectin
(E-Sel), and von Willebrand factor (vWF) (2–6), as well as
endothelial vasoactive peptides, such as angiotensinogen
and angiotensin-converting enzyme (ACE) (7).
Hyperinsulinemia and IR have been involved in vascular
reactivity. In the absence of IR, insulin has a direct vaso-
dilatory effect (8, 9). However, reports assessing in vivo
vascular reactivity in humans demonstrated that the
endothelium-dependent vasodilatory response was altered
in experimental mild hyperinsulinemic subjects (10) and in
obese individuals who displayed IR (11, 12).
In contrast, a growing body of evidence has suggested the
role of low grade inflammation as a link between obesity and
IR, and endothelial dysfunction. Increased serum levels of
inflammatory biomarkers such as C-reactive protein (CRP)
have been reported in obese subjects and have been related
to the degree of insulin sensitivity and endothelial function
(2, 3, 13). In fact, elevation of proinflammatory cytokines,
such as TNF- and IL-6, could cause IR by interfering with
insulin signaling and down-regulating peroxisomal prolif-
erator-activated receptor- receptors (14, 15). Several mech-
anisms have been suggested to elucidate the obesity-related,
low grade inflammation. Firstly, fat tissue is an important
source of proinflammatory, i.e. TNF and IL-6, and antiin-
flammatory, i.e. adiponectin, cytokines. Secondly, IR can
cause inflammation to rise by interfering with the antiin-
flammatory effect of insulin (16). Finally, obesity is charac-
terized by oxidative stress, mainly from excessive macronu-
trient intake or increased metabolic rate, which might be
partly responsible for the inflammatory response (17). In-
deed, a load of lipid or glucose to obese or normal subjects
leads to an increase in reactive oxygen species generation,
inflammation, and lower vascular reactivity (18). Con-
versely, dietary restriction in obese patients leads to a sig-
nificant reduction in oxidative stress and inflammation (19).
By contrast, higher TNF- and IL-6 serum levels reported
in morbidly obese patients decreased after weight loss in
some reports (20), but not in others (21, 22). Also, the met-
abolic and inflammatory responses that occur in the weight-
losing, morbidly obese patient after bariatric surgery are
scarcely reported. In view of the fact that morbid obesity is
First Published Online October 26, 2004
Abbreviations: ACE, Angiotensin-converting enzyme; AUC, area un-
der the curve; Bk, bradykinin; BMI, body mass index; CRP, C-reactive
protein; E-Sel, E-selectin; F, fat mass; FSIVGTT, frequently sampled iv
glucose tolerance test; ICAM-1, intercellular adhesion molecule-1; IR,
insulin resistance; NE, norepinephrine; l-NMMA, NG-monomethyl-l-
arginine; NO, nitric oxide; PAI-1, plasminogen activator inhibitor-1;
P-Sel, P-selectin; SA, sialic acid; SG, glucose effectiveness at basal insulin;
SI, insulin sensitivity index; SNP, sodium nitroprusside; TB, thrombo-
modulin; TNFR1, TNF receptor type 1; VCAM-1, vascular cell adhesion
molecule-1; VD, venodilatory response; vWF, von Willebrand factor.
JCEM is published monthly by The Endocrine Society (http://www.
endo-society.org), the foremost professional society serving the en-
docrine community.
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(1):316–322
Printed in U.S.A. Copyright © 2005 by The Endocrine Society
doi: 10.1210/jc.2003-032059
316
associated with IR, endothelial dysfunction, and low grade
inflammation, we tested the hypothesis that body weight loss
4 months after bariatric surgery might improve IR, and,
hence, endothelial function and inflammation. We therefore
assessed insulin sensitivity by frequently sampled iv glucose
tolerance test (FSIVGTT). We also measured vascular reac-
tivity and other circulating endothelial markers to assess
endothelial function. Acute phase proteins and cytokines
were measured to test the innate inflammatory response.
Relationships among metabolic, endothelial, and inflamma-
tory variables were investigated to determine the mecha-
nisms operating in the group of weight-losing, morbidly
obese patients. For comparison, healthy matched control
subjects were also studied
Subjects and Methods
Subjects
A group of 26 (23 women and three men) morbidly obese patients
[age, 39.0  10.0 (mean  sd); body mass index (BMI), 46.2 (range,
36–61)] from a waiting list for bariatric surgery at University Hospital
of Cantabria (Spain) were included in the study protocol. A group of 26
healthy, normal weight subjects (BMI, 23; range, 19–26), matched for age
and sex, was included as the control group. A complete medical history
and physical examination were performed for each subject. Subjects with
diabetes mellitus, cardiovascular disease, psychiatric problems, or al-
cohol abuse; those receiving treatment with lipid-lowering agents, as-
pirin, glucocorticoids, antineoplastic agents, and bronchodilators; as
well as subjects who had smoked within the last 3 months before the
present study were excluded. All women were studied randomly with
respect to their menstrual cycle. Each subject gave written informed
consent to participate in this study, which was approved by the ethical
committee of our institution.
Study protocol
The morbidly obese patients were evaluated before (baseline) and
4.2  0.8 (mean  sd) months after surgery (fourth month). Each eval-
uation consisted of clinical and body composition measurements, blood
sample extractions, as well as insulin sensitivity and vascular reactivity
tests. Most of the basal blood chemical parameters were also determined
in the control group. Two different surgical procedures were performed
in obese patients; 18 patients underwent a classical vertical banded
gastroplasty according to the technique proposed by Mason (23), and
eight patients underwent a bilious-pancreatic diversion according to the
technique proposed by Scopinaro (24). No significant postoperative
complications occurred that prevented the patients from completing the
study protocol.
Clinical, body composition, and blood
sample measurements
Every measurement was performed after an overnight fast of 12 h at
the metabolic unit. A general physical examination was performed by
a study physician. The systolic and diastolic blood pressure readings
were recorded as the mean of two measurements with the subjects
seated. Subjects’ weight, height, and waist and hip circumferences were
also obtained. Body fat was estimated by bioelectric impedance using a
monofrequency and tetrapolar device (Bodystat 1500, Bodystat Ltd., Isle
of Man, UK). Blood samples were drawn from an antecubital vein with
a 19-gauge needle without venous stasis. Plasma glucose, total serum
cholesterol, and triglycerides were measured using a Dax analyzer
(Technicon Instruments, Tarrytown, NY). Plasma insulin was measured
by RIA (ERIA Diagnostics Pasteur, Marnes la Coquette, France); C pep-
tide was measured using an immunoradiometric assay (Diasorin, Ver-
celli, Italy). vWF (Asserachrom, Roche, Mannheim, Germany), plasmin-
ogen activator inhibitor-1 (PAI-1) (Innogenetics, Zwijnaarde, Belgium),
E-Sel (Bender Med Systems, Vienna, Austria), soluble P-selectin (P-Sel;
Bender Medical Systems), thrombomodulin (TB; Asserachrom, Diag-
nostica Stago, Asnieres-Sur-Seine, France), ICAM-1 (Bender Medical
Systems), soluble vascular cell adhesion molecule-1 (VCAM-1; Bender
Medical Systems), TNF- (R&D Systems, Oxon, UK), soluble TNF-
receptor type 1 (TNFR1; R&D Systems), soluble TNFR2 (R&D Systems),
and IL-6 (R&D Systems, Minneapolis, MN) were measured in plasma
using an ELISA method. Intra- and interassay coefficients of variation
in all assays were lower than 7% and 14%, respectively. ACE and sialic
acid (SA) were measured with a Hitachi 704 analyzer (Hitachi, Tokyo,
Japan) using reagents from Sigma-Aldrich Corp. (St Louis, MO) and
Roche, respectively. Plasma and platelet cGMP were measured as pre-
viously described (25) using a specific enzyme immunoassay (Biotrak,
Amersham Biosciences, Little Chalfont, UK). Intra- and interassay co-
efficients of variation were 8.7% and 11.2%, respectively. Plasma CRP
levels were measured by means of immunonephelometry in a nephe-
lometer analyzer II (Behring, Marburg, Germany) using reagents from
Behring (Sommerville, NJ).
Insulin sensitivity test
IR was assessed using Bergman’s minimal model analysis based on
a mathematical quantification of glucose and insulin serum levels from
a 12-time point, insulin-enhanced FSIVGTT (26). This analysis provides
two indicators, the insulin sensitivity index (SI), which is the insulin-
mediated glucose disposal, and glucose effectiveness at basal insulin
(SG), which is the glucose-mediated glucose disposal. Briefly, in the
fasted state, glucose (0.3 g/kg) and insulin (0.03 U/kg) were injected iv
at 0 and 20 min, respectively. Blood samples were drawn at 0, 2, 4, 8, 19,
22, 30, 40, 50, 70, 100, and 180 min for determination of glucose and
insulin serum levels. The area under the curve for insulin in response
to iv glucose was determined between 0 and 19 min (AUC-I0–19) using
the trapezoidal rule of each FSIVGTT.
Vascular reactivity test
To assess endothelial vasodilatory function, the vascular reactivity of
one of the dorsal hand veins, measured by a linear differential trans-
former technique before and after bradykinin (Bk; endothelium-depen-
dent nitric oxide (NO)-mediated venodilation) and sodium nitroprus-
side (SNP) (endothelium-independent NO-mediated venodilation)
infusion, was determined as previously described (27). Briefly, the study
was carried out in a temperature-controlled room (28–30 C), and an
overnight fast was required. A 23-gauge butterfly needle was inserted
into a preselected vein on the back of the hand. A tripod holding a linear
variable differential transformer was attached to the perivenous surface.
The linear transformer signaling records stood for variations in venous
diameter. All records were taken under a congestive pressure of 40 mm
Hg. The saline-induced venous diameter was considered 100% veno-
dilation. Thereafter, increasing norepinephrine (NE) doses were infused
to achieve a progressive venous constriction. The NE dose producing
50% reduction in venous diameter (0% venodilation) was administered
at a fixed flow rate throughout the test. Both the Bk- (Bk-VD) and
SNP-induced (SNP-VD) venodilatory responses were depicted as the
percent venous diameter change from NE-induced (0%) venodilation.
The inhibitory effect of NG-monomethyl-l-arginine (l-NMMA) on Bk-VD
was also shown.
Statistical analysis
Data are presented as the mean  sem. For parametrically distributed
data, comparisons were made using the paired t test for data within the
obese group and ANOVA followed by Bonferroni post hoc test for data
between groups. For nonparametrically distributed data, Wilcoxon and
Kruskal-Wallis tests were used where appropriate. Correlations be-
tween changes in the variables were tested using univariate analyses
(Pearson’s or Spearman’s correlation where appropriate). P  0.05 was
considered statistically significant.
Results
Clinical and metabolic effects
The effect of bariatric surgery on clinical, anthropometric,
and adiposity measurements are shown in Table 1. Body
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weight, BMI, waist circumference, hip circumference, and fat
mass (F) decreased markedly 4 months after surgery. SI was
markedly increased, even though SG remained unchanged.
Baseline C peptide, a marker of endogenous insulin secre-
tion, and AUC-I0–19, indicating the insulin response to the
glucose challenge during FSIVGTT, were also decreased sig-
nificantly (Table 1).
Vascular reactivity testing
The Bk-VD significantly increased 4 months after surgery
compared with that at baseline (76.76  4.71% vs. 91.74 
2.90%; P  0.01). This response was markedly inhibited by
concomitant administration of the NO production inhibitor
l-NMMA at both times (65.94  7.08% vs. 60.80  5.44%; not
significant). Furthermore, SNP-VD (endothelium-indepen-
dent), which was higher than the Bk-VD at baseline, re-
mained unchanged after surgery (97.87  1.06% vs. 95.83 
1.61%; not significant). By the fourth month after surgery, no
differences between Bk-VD and SNP-VD were found (Fig. 1).
Endothelial and inflammatory biomarkers
Table 2 shows the circulating endothelial and inflamma-
tory mediators before and after surgery in morbidly obese
patients. These values were compared with the data obtained
from the control group. ACE levels were not different among
groups. vWF levels decreased after surgery, but remained
significantly higher than those in the control group. E-Sel
levels decreased after surgery to the levels found in the
control group. P-Sel levels decreased significantly after bari-
atric surgery in the obese group. ICAM-1 levels remained
unchanged among groups. VCAM-1 levels were higher in
obese patients after surgery compared with those in the
baseline and control groups; no differences at baseline be-
tween groups were found. TB remained unchanged among
groups. PAI-1 levels, which were higher at baseline in obese
patients, decreased after surgery to values similar to those in
the control group. Plasma cGMP levels were lower in pa-
tients with morbid obesity than in the control group and
remained unchanged after surgery. Platelet cGMP levels re-
mained unchanged among groups. SA levels, which were
higher at baseline in the obese group, decreased to values
similar to those in the control group. TNF- levels were
higher in obese patients and remained unchanged after bari-
atric surgery. TNFR1 levels were higher in obese patients,
and a nonsignificant decrease after bariatric surgery was
observed. TNFR2 levels were higher in obese patients and
increased after bariatric surgery. IL-6 levels were higher in
obese patients, but remained unchanged after bariatric sur-
gery. CRP levels were higher in obese patients and decreased
after surgery to values higher than those in the control group.
Circulating SA levels, which were higher in the obese group,
decreased after surgery to levels similar to those in the con-
trol group.
Correlational analysis in morbid obesity
To examine the mechanisms of the marked weight loss
following bariatric surgery on endothelial function and in-
flammation, we examined correlations among changes in
indexes of insulin action, changes in indexes of adiposity,
changes in endothelium-dependent vasodilation, and changes
in endothelial and inflammatory markers (Table 3). Signifi-
cant correlations among the anthropometric and adiposity
measurements were found between changes in SI and BMI,
and between changes in waist circumference and F. Also,
changes in SI were found to be correlated with changes in TB
and strongly with changes in CRP among endothelial and
inflammatory markers, respectively. The only relationship of
changes in Bk-VD that we found was with changes in SA,
which suggested inflammation to impair endothelium-
TABLE 1. Clinical measurements and indices of sensitivity and
secretion of insulin in morbidly obese patients before (Baseline)
and after (4th month) bariatric surgery
Baseline 4th month
Weight (kg) 126.3  5.7 99.6  4.3a
BMI (kg/m2) 46.2  1.3 36.7  1.2a
Waist circumference (cm) 127.9  3.4 115.1  3.1a
Hip circumference (cm) 133.9  2.6 119.9  2.2a
F (kg) 63.9  3.3 42.4  2.5a
Systolic blood pressure (mm Hg) 134.8  3.8 128.1  3.2b
Diastolic blood pressure (mm Hg) 91.4  4.0 86.0  2.4b
Total cholesterol (mmol/liter) 5.0  0.2 4.3  0.2c
Triglycerides (mmol/liter) 1.4  0.1 1.0  0.1a
SI (10
4/min1U/ml) 0.87  0.16 2.38  0.29a
SG (10
2/min) 2.20  0.36 1.86  0.22
C Peptide (g/liter) 4.0  0.3 2.1  0.2a
AUC-I0–19 (IU/ml) 1399.7  203.2 785.6  110.2
a
Data are the mean  SEM. AUC-I0–19, Area under curve for insulin.
Insulin conversion factor (CF) to picomoles per liter, 7.175.
a P  0.001 vs. baseline.
b P  0.05 vs. baseline.
c P  0.01 vs. baseline.
FIG. 1. Vascular reactivity testing in morbidly obese patients. Dorsal
hand vein dilations in response to Bk (Bk-VD), Bk with l-NMMA
(Bkl-NMMA-VD), and SNP (SNP-VD) were measured using a linear
differential transformer technique in the same patients before (base-
line; ) and after bariatric surgery (fourth month; f). The vasodila-
tory effects were expressed as the percent dilation between 0 and
100% obtained by NE and normal saline infusions, respectively. Data
are the mean  SEM. †, P  0.01 vs. baseline; ‡, P  0.001 vs. Bk-VD.
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dependent venodilation. Amongst the changes in circulating
endothelial markers, the largest were between ICAM-1 and
TNFR2, VCAM and TNFR2, vWF and SA, E-Sel and SA, E-Sel
and TNFR2, TB and SA, ACE and SA, and PAI-1 and F. Most
of the changes in inflammatory markers were correlated with
each other. The results of both correlational and mean dif-
ference analyses in the group of patients that underwent
vertical banded gastroplasty surgery were similar to those in
the bilious-pancreatic diversion group, even though several
significant associations were lost in the correlational analysis
as the number of patients decreased.
Discussion
The present study confirms that in morbidly obese, non-
diabetic patients, a marked weight loss 4 months after bari-
atric surgery results in a marked reduction in both IR and
basal and stimulated insulin secretion. In agreement with
previous reports, SI increased, insulin secretion decreased,
and SG remained unchanged, suggesting a major role for
insulin-mediated mechanisms in the pathogenesis of IR in
morbid obesity (28). In addition to reduction in IR, this
marked weight loss has been found to be associated with
improvement in the clustering of obesity-related metabolic
TABLE 2. Circulating levels of both endothelial and inflammatory biomarkers in morbidly obese patients before (Baseline) and after
bariatric surgery (4th month) compared with a normative values of these mediators in a healthy, pairwise-matched, control group
Variables Obese baseline Obese 4th month Control baseline
ACE (U/liter) 34.76  4.06 30.50  3.29 40.53  3.15
vWF (%) 82.33  6.16 72.94  7.54a 29.99  3.15b,c
Soluble E-Sel (ng/ml) 45.31  6.17 24.92  2.88b 23.49  2.50b
Soluble P-Sel (ng/ml) 112.58  14.35 78.70  7.84b 96.70  7.06
ICAM-1 (ng/ml) 206.27  13.65 202.16  11.43 182.08  9.71
VCAM-1 (ng/ml) 1012.10  50.40 1268.84  61.98b 937.28  51.50c
TB (ng/ml) 29.28  2.23 30.58  1.93 29.50  2.34
PAI-1 (ng/ml) 161.08  9.11 98.24  8.45b 77.32  6.12b
cGMP (plasma; pg/ml) 4.35  0.24 4.36  0.30 9.38  1.34b,c
cGMP (platelet; pg/ml) 1.27  0.09 1.28  0.11 0.89  0.14
Sialic acid (mg/dl) 89.65  2.46 83.53  2.30a 80.18  2.10a
TNF (pg/ml) 2.88  0.22 2.72  0.22 1.35  0.21b,c
TNFR1 (pg/ml) 1378.99  49.39 1279.53  51.31 1111.61  45.75b
TNFR2 (pg/ml) 2329.76  79.14 2572.35  96.43a 1979.73  74.45b,c
IL-6 (pg/ml) 4.93  0.70 4.92  0.69 3.17  0.91b,c
CRP (mg/dl) 0.63  0.10 0.40  0.06a 0.15  0.04b,c
Data are the mean  SEM.
a P  0.05 vs. baseline (obese).
b P  0.004 vs. baseline (obese).
c P  0.001 vs. 4th month (obese).
TABLE 3. Correlations of changes among body composition measurements, indices of both sensitivity and secretion of insulin, circulating
endothelial markers, and inflammatory changes and inflammatory markers
F SI Bk-VD TNF TNFR1 TNFR2 IL-6 CRP SA
BMI 0.90a 0.45b 0.06 0.23 0.11 0.01 0.31 0.35 0.08
F 0.07 0.21 0.13 0.01 0.25 0.44b 0.05
WC 0.42b 0.61c 0.19 0.25 0.06 0.35 0.26 0.01 0.15
SI 0.47b 0.22 0.25 0.14 0.12 0.01 0.60c 0.18
AUC1 0.01 0.29 0.16 0.20 0.06 0.14 0.11 0.41b 0.24
Bk-VD 0.07 0.22 0.05 0.07 0.07 0.00 0.16 0.45b
ICAM-1 0.17 0.25 0.06 0.15 0.22 0.49c 0.41b 0.34 0.28
VCAM 0.04 0.38 0.09 0.21 0.25 0.48c 0.36 0.05 0.35
PAI-1 0.48c 0.22 0.05 0.23 0.06 0.22 0.16 0.35 0.11
vWF 0.05 0.10 0.18 0.16 0.19 0.28 0.17 0.12 0.44b
E-Sel 0.28 0.33 0.24 0.18 0.12 0.42b 0.01 0.30 0.49c
P-Sel 0.15 0.11 0.17 0.07 0.08 0.06 0.04 0.05 0.05
TB 0.18 0.45b 0.13 0.00 0.26 0.04 0.21 0.03 0.47b
ACE 0.02 0.09 0.05 0.35 0.35 0.36 0.38 0.35 0.46b
TNF 0.21 0.25
TNFR1 0.13 0.14 0.58c
TNFR2 0.01 0.12 0.36 0.54c
IL-6 0.25 0.01 0.06 0.52c 0.51c
CRP 0.44b 0.60c 0.33 0.49c 0.45b 0.38b
SA 0.05 0.18 0.13 0.45b 0.52c 0.70a 0.56c
Data are correlation coefficients. , Changes from basal to 4th month. AUC-10–19, Area under curve for insulin; WC, waist circumference.
a P  0.001.
b P  0.05.
c P  0.01.
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syndrome, blood pressure, triglycerides, and cholesterol.
These findings make our model suitable to study the mech-
anisms by which the improvement in obesity-related meta-
bolic syndrome might modify cardiovascular risk.
The present study demonstrated that in morbid obesity,
venous vasodilatory function induced by Bk, an endothelium-
dependent vasodilator (29), improved after bariatric sur-
gery, and NO production and NO synthase activity are in-
volved in the improvement in vascular reactivity. Resistance
to the vasodilatory effect of insulin (30), inflammatory cy-
tokines (31), and the obesity-related increased formation of
reactive oxygen species, including superoxide (18), have
been reported to play a major role in the impairment of
obesity-related (12) endothelial NO-mediated vasodilation.
In this group with morbid obesity, the correlation analysis
among changes in Bk-VD and SA suggests that over the
medium term, low grade inflammation may be the link be-
tween obesity-related IR and vasodilatory function.
In addition to vasodilatory function, we studied several
circulating endothelial biochemical markers. This study
shows that in nondiabetic, morbidly obese patients, levels of
most of the endothelial dysfunction biomarkers are higher
than those in control lean subjects. These chemical mediators
that arise from endothelial cells in response to inflammation
or damage, regulating the attachment and transmigration of
leukocytes across endothelial line, are likely to play a role in
the development and/or progression of atherosclerosis, and
they can be used clinically as markers of cardiovascular
events (32). In agreement with previous reports, the higher
levels of P-Sel decrease after bariatric surgery (33). We also
found, for the first time to our knowledge, that levels of E-Sel
and vWF decrease after weight loss in morbid obesity. The
observation of increased circulating cellular adhesion mol-
ecules and their relationships with the inflammatory markers
led us to suggest endothelial activation as a link between
obesity and atherosclerosis. In contrast, even though no dif-
ferences were found between the obese patients and the
control group at baseline, VCAM increased slightly. Higher
plasma VCAM-1 levels have been reported in obesity by
some researchers, but not by others (32, 33), and some con-
troversy exists over the clinical significance of circulating
VCAM-1 to vascular damage (34). This study failed to show
any change in ACE, ICAM-1, platelet cGMP, and TB between
groups. Changes in these molecules have been found in
relation to moderate obesity or diabetes-related IR (7, 33, 35,
36). Differences in the experimental models, i.e. moderate vs.
severe obesity, may explain these discrepancies. The endo-
thelium-derived molecule involved in vascular hemostasis,
PAI-1, is also expressed in adipose tissue and is related to
obesity and IR (37). In the morbidly obese group, weight loss
after bariatric surgery normalized the augmented plasma
PAI-1 levels in accordance with previous reports (38). Fur-
thermore, the PAI-1 changes were strongly correlated with
measurements of adiposity. These findings suggest that body
weight loss improves, at least partially, the prothrombotic
tendency observed in severe obesity.
This study shows that the low grade inflammation im-
proved due to the weight-losing effect of bariatric surgery,
and this improvement has been strongly related to insulin
sensitivity and adiposity. According to previous reports, el-
evation of both the acute phase mediators, CRP and SA, and
the proinflammatory cytokines, TNF and IL-6, has charac-
terized morbid obesity as a low grade inflammatory process
of the innate immune system (39, 40). The strong relationship
between changes in SI and adiposity with changes in CRP in
the morbidly obese group suggests that the state of IR results,
at least partly, in the development of inflammation by in-
terfering with the antiinflammatory effect of insulin (16).
Also, it suggests that adiposity, which is characterized by
oxidative stress, mainly from excessive macronutrient intake
or increased metabolic rate, might induce inflammation by
activation of the redox-sensitive proinflammatory transcrip-
tion factor, nuclear factor-B (41). Indeed, administration of
a load of lipid or glucose to obese or normal subjects leads
to an increase in reactive oxygen species generation, inflam-
mation, and lower vascular reactivity (18); in contrast, di-
etary restriction in obese patients leads to a significant
reduction in oxidative stress and inflammation (19). Alter-
natively, fat tissue is an important source of proinflamma-
tory, i.e. TNF and IL-6, and antiinflammatory, i.e. adiponec-
tin, cytokines, which, in turn, might result in IR (42). In
contrast, this study failed to show any change in TNF- and
IL-6 4 months after surgery, whereas a nonsignificant de-
crease in TNFR1 and a slight increase in TNFR2 serum levels
were observed. Although these findings could not be ex-
plained by the findings of this study, it appears that inflam-
matory pathways involving the TNF- system and IL-6 re-
main activated. In obese patients, it has been stated that body
weight loss induced by a low calorie diet and behavior mod-
ifications lower circulating TNF- and IL-6 levels (20, 33). In
contrast, the absence of changes in these inflammatory cy-
tokines has been recently reported in very active, weight-
losing patients induced by a very low calorie diet (43) or
bariatric surgery (21, 22), suggesting a role of the metabolic
stress of relative starvation in the inflammatory response
(44). Alternatively, due to the fact that our patients remained
relatively obese, it might be hypothesized that a certain
amount of adiposity must be lost before any effect on these
cytokines is observed. Additional studies in different human
weight-losing models are required to elucidate the mecha-
nisms underlying the effect of body weight reduction on
inflammatory pathways that involve TNF- and IL-6.
Although the physiological significance of plasma levels of
the soluble fraction of TNF- receptors is not fully under-
stood, it has been previously described their relationship
with obesity (45). We found that TNF- receptors were pos-
itively related to adiposity and endothelial dysfunction
markers. Moreover, the correlation between the increases in
VCAM-1 and TNFR2 levels after surgery suggests that the
persistence in the activation of this low grade inflammation
pathway might be involved in the lack of decrease in
VCAM-1 levels that we observed.
Our findings showed the associations of endothelial func-
tion and adiposity with CRP and SA to be apparently het-
erogeneous. However, the correlational analysis of changes
in these inflammatory markers showed that they were
closely related to each other throughout this study. Also,
discordance between the plasma concentrations of different
acute phase proteins is relatively common, because they are
individually regulated and have different patterns of pro-
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duction (46). Furthermore, blood SA levels reflect an inte-
grated measure of the acute phase response, because many
of the acute phase proteins are glycoproteins with SA at the
terminal of the oligosaccharide chain (47), which might be
modified by variations in blood levels of most acute phase
proteins as well as their posttranscriptional sialylation. Re-
cent reports have indicated the difficulty of characterizing
this low grade inflammatory state on the basis of a single
marker, suggesting the use of a summary measure of several
markers as an inflammatory score to better realize the in-
flammatory state (48). Finally, because the possible correla-
tion between venous and arterial dysfunction remains to be
demonstrated in morbid obesity, discrepancies with previ-
ous reports in the associations between inflammatory mark-
ers and vasodilatory response (49, 50) may be related to
different study protocols, i.e. venous vs. invasive and non-
invasive arterial models (29).
Taken together, these findings show that in morbidly
obese patients after bariatric surgery, weight loss, insulin
sensitivity, endothelial function, as well inflammatory re-
sponse improve in parallel over the medium term. Changes
in IR and obesity status appear to be involved in the decrease
in the inflammatory response, although IL-6 and TNF- sys-
tems remained activated 4 months after bariatric surgery.
These findings suggest that metabolic events and mediators
other than TNF- and IL-6, such as insulin and oxidative
stress, seem to play a role in serum levels of CRP and SA in
our model of morbid obesity. Throughout this study, E-Sel
and PAI-1, and CRP and SA have been shown to be the
earliest and most consistent markers of endothelial dysfunc-
tion and inflammatory response, respectively. The practical
utility of these markers in cardiovascular risk evaluation and
in the results of interventional procedures in morbid obesity
should be considered.
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